[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11201406903SA - Cell culture compositions and methods for polypeptide production - Google Patents

Cell culture compositions and methods for polypeptide production

Info

Publication number
SG11201406903SA
SG11201406903SA SG11201406903SA SG11201406903SA SG11201406903SA SG 11201406903S A SG11201406903S A SG 11201406903SA SG 11201406903S A SG11201406903S A SG 11201406903SA SG 11201406903S A SG11201406903S A SG 11201406903SA SG 11201406903S A SG11201406903S A SG 11201406903SA
Authority
SG
Singapore
Prior art keywords
south san
san francisco
dna way
international
cell culture
Prior art date
Application number
SG11201406903SA
Other languages
English (en)
Inventor
Steven J Meier
Melissa S Mun
Natarajan Vijayasankaran
Sharat Varma
Yi Yang
Boyan Zhang
Silvana R Arevalo
Martin Gawlitzek
Veronica Carvalhal
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49380652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201406903S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of SG11201406903SA publication Critical patent/SG11201406903SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/005—Protein-free medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201406903SA 2012-04-24 2013-04-24 Cell culture compositions and methods for polypeptide production SG11201406903SA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261637778P 2012-04-24 2012-04-24
US201261637780P 2012-04-24 2012-04-24
US13/841,864 US20130281355A1 (en) 2012-04-24 2013-03-15 Cell culture compositions and methods for polypeptide production
PCT/US2013/037992 WO2013163294A1 (en) 2012-04-24 2013-04-24 Cell culture compositions and methods for polypeptide production

Publications (1)

Publication Number Publication Date
SG11201406903SA true SG11201406903SA (en) 2014-12-30

Family

ID=49380652

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201406903SA SG11201406903SA (en) 2012-04-24 2013-04-24 Cell culture compositions and methods for polypeptide production
SG10201810830UA SG10201810830UA (en) 2012-04-24 2013-04-24 Cell culture compositions and methods for polypeptide production

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201810830UA SG10201810830UA (en) 2012-04-24 2013-04-24 Cell culture compositions and methods for polypeptide production

Country Status (22)

Country Link
US (2) US20130281355A1 (ru)
EP (2) EP2841561B1 (ru)
JP (4) JP6367792B2 (ru)
KR (2) KR102115052B1 (ru)
CN (2) CN104428409A (ru)
AR (1) AR090822A1 (ru)
AU (2) AU2013251647B2 (ru)
BR (1) BR112014026308A8 (ru)
CA (1) CA2871006C (ru)
ES (1) ES2716301T3 (ru)
HK (1) HK1208496A1 (ru)
HR (1) HRP20190484T1 (ru)
IL (1) IL235235A0 (ru)
MX (2) MX363493B (ru)
MY (1) MY181513A (ru)
NZ (1) NZ701791A (ru)
PL (1) PL2841561T3 (ru)
RU (2) RU2678142C2 (ru)
SG (2) SG11201406903SA (ru)
SI (1) SI2841561T1 (ru)
WO (1) WO2013163294A1 (ru)
ZA (2) ZA201408092B (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
AR095348A1 (es) * 2013-03-15 2015-10-07 Genentech Inc Medios de cultivo celular y métodos de producción de anticuerpos
SG10201809452RA (en) * 2013-03-15 2018-11-29 Genentech Inc Cell culture compositions with antioxidants and methods for polypeptide production
US9598667B2 (en) * 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
GB201708655D0 (en) 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods
CN110945593A (zh) * 2017-06-16 2020-03-31 通用电气健康护理生物科学股份公司 用于预测生物反应器中的过程的产出和对生物反应器中的过程建模的方法
EP3492582A1 (en) 2017-12-01 2019-06-05 UCB Biopharma SPRL Cell culture methods
CN108823267B (zh) * 2018-06-25 2020-05-08 深圳市菲鹏生物制药股份有限公司 调节cho-k1表达系统所分泌抗体的酸性峰含量的方法
EP4051790A4 (en) * 2019-10-31 2023-11-01 William Marsh Rice University GENETICALLY ENGINEERED CELLS FOR CONTROLLED PRODUCTION
IL288360B2 (en) 2019-12-06 2023-09-01 Regeneron Pharma Anti-vegf protein preparations and methods for their production
CN115038793A (zh) * 2020-01-31 2022-09-09 中外制药株式会社 含有抑制着色的多肽的组合物的制备方法
JP7404930B2 (ja) 2020-02-26 2023-12-26 富士フイルムビジネスイノベーション株式会社 発光装置、光学装置及び計測装置
JP7404929B2 (ja) 2020-02-26 2023-12-26 富士フイルムビジネスイノベーション株式会社 発光装置、光学装置及び計測装置
CA3182893A1 (en) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer
GB202012991D0 (en) 2020-08-20 2020-10-07 Ucb Biopharma Sprl Cell culture processes
IL303951A (en) * 2020-12-22 2023-08-01 Novartis Ag Methods for reducing the oxidation level of cysteine residues in recombinantly secreted protein during cell culture
GB202105424D0 (en) 2021-04-16 2021-06-02 UCB Biopharma SRL Cell culture processes
CA3229424A1 (en) 2021-09-02 2023-03-09 Boehringer Ingelheim International Gmbh Method of determining a future color value or corresponding property and arrangement therefor
KR102682066B1 (ko) * 2021-10-12 2024-07-05 프레스티지바이오로직스 주식회사 항체 집단의 제조 방법

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
JPS5863385A (ja) 1981-10-02 1983-04-15 ハナ・バイオロジツクス・インコ−ポレ−テツド 免疫系由来の細胞用培地
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4816401A (en) 1985-09-09 1989-03-28 University Of Rochester Serum free cell culture medium
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JPH03180176A (ja) * 1989-11-16 1991-08-06 W R Grace & Co 細胞培養のための基礎栄養培地
ES2083469T3 (es) 1989-11-22 1996-04-16 Genentech Inc Peptido asociado a una latencia y utilizaciones del mismo.
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
JPH07102147B2 (ja) * 1992-03-16 1995-11-08 株式会社ミドリ十字 ヒト血清アルブミンの着色抑制方法
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5512477A (en) 1994-04-21 1996-04-30 Genzyme Corporation Serum-free medium supplement
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ATE222598T1 (de) * 1996-04-19 2002-09-15 Nestle Sa Menschliche immortalisierte colon- epithelialzellen
JP4543402B2 (ja) * 1996-10-10 2010-09-15 ライフ テクノロジーズ コーポレーション 植物由来栄養素を含む動物細胞培養培地
US20020012991A1 (en) 1997-04-07 2002-01-31 Florence Chua Nee Ho Kit Fong Cell culture media for enhanced protein production
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
US20060286668A1 (en) 1999-04-30 2006-12-21 Invitrogen Corporation Animal-cell culture media comprising non-animal or plant-derived nutrients
JP2005505240A (ja) 2001-02-15 2005-02-24 セントカー・インコーポレーテツド 培養された哺乳動物細胞のための化学的合成培地
JP2004532642A (ja) 2001-06-13 2004-10-28 ジェネンテック・インコーポレーテッド 動物細胞の培養方法と動物細胞でのポリペプチド産生
GB0208041D0 (en) * 2002-04-08 2002-05-22 Lonza Biologics Plc Method of culturing animal cells
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
GB0304799D0 (en) * 2003-03-03 2003-04-09 Glaxosmithkline Biolog Sa Novel method
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
CA2542125A1 (en) * 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
US7294484B2 (en) * 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2005302516A1 (en) 2004-10-29 2006-05-11 Centocor, Inc. Chemically defined media compositions
CN100569940C (zh) 2006-08-16 2009-12-16 华东理工大学 人胚胎肾(hek)293细胞无血清培养基
BRPI0716762A2 (pt) * 2006-09-13 2013-09-24 Abbott Lab melhorias da cultura celular
US20110070225A1 (en) 2006-11-12 2011-03-24 Pierre Goldbach Beta antibody parenteral formulation
WO2008084857A1 (ja) * 2007-01-12 2008-07-17 Nippon Sheet Glass Company, Limited 三次元細胞培養担体およびそれを用いた細胞培養方法
WO2009014272A1 (en) * 2007-07-20 2009-01-29 Dongguk University Industry-Academic Cooperation Foundation Method for the preparation of dermal papilla tissue employing mesenchymal stem cells
MX2010002249A (es) * 2007-08-31 2010-03-17 Amgen Inc Formulacion de proteina de estado solido.
PL2310523T3 (pl) * 2008-04-17 2015-10-30 Wyeth Llc Sposoby zwiększonego wytwarzania białek morfogenetycznych kości
RU2011116319A (ru) * 2008-09-26 2012-11-10 Шеринг Корпорейшн (US) Производство высокого титра антител
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US9540426B2 (en) * 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
USRE48864E1 (en) 2010-04-26 2021-12-28 Novartis Ag Cell culture medium

Also Published As

Publication number Publication date
RU2018146497A (ru) 2019-02-04
CN104428409A (zh) 2015-03-18
ZA201408092B (en) 2019-03-27
JP7323272B2 (ja) 2023-08-08
EP2841561A1 (en) 2015-03-04
KR102115052B1 (ko) 2020-05-25
CN111440758A (zh) 2020-07-24
RU2678142C2 (ru) 2019-01-23
AU2019202259A1 (en) 2019-04-18
CA2871006C (en) 2021-05-25
BR112014026308A2 (pt) 2017-06-27
EP3533864A1 (en) 2019-09-04
AU2019202259B2 (en) 2021-11-11
US20240093143A1 (en) 2024-03-21
MX363493B (es) 2019-03-26
WO2013163294A1 (en) 2013-10-31
US20130281355A1 (en) 2013-10-24
JP6367792B2 (ja) 2018-08-01
MX2019003427A (es) 2020-11-12
NZ701791A (en) 2017-03-31
HRP20190484T1 (hr) 2019-05-17
JP2021104023A (ja) 2021-07-26
JP2023156371A (ja) 2023-10-24
AU2013251647B2 (en) 2019-04-04
HK1208496A1 (en) 2016-03-04
SI2841561T1 (sl) 2019-04-30
PL2841561T3 (pl) 2019-05-31
KR20150003351A (ko) 2015-01-08
RU2014147018A (ru) 2016-06-10
IL235235A0 (en) 2014-12-31
BR112014026308A8 (pt) 2021-06-01
KR20200057795A (ko) 2020-05-26
SG10201810830UA (en) 2018-12-28
MY181513A (en) 2020-12-24
ES2716301T3 (es) 2019-06-11
EP2841561B1 (en) 2019-01-16
ZA201707452B (en) 2021-03-31
CA2871006A1 (en) 2013-10-31
JP2018183154A (ja) 2018-11-22
AR090822A1 (es) 2014-12-10
AU2013251647A1 (en) 2014-12-18
MX2014012838A (es) 2015-10-22
JP2015515281A (ja) 2015-05-28
KR102339106B1 (ko) 2021-12-15

Similar Documents

Publication Publication Date Title
SG11201406903SA (en) Cell culture compositions and methods for polypeptide production
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201407417VA (en) Encoding and reconstruction of residual data based on support information
SG11201804375WA (en) Compositions and methods for internalizing enzymes
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201804398XA (en) Method for producing rna molecule compositions
SG11201407768QA (en) Generating pluripotent cells de novo
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201407859YA (en) Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201407427WA (en) Extreme pcr
SG11201408261UA (en) Syringe
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
SG11201407669QA (en) Methods for improving safety of blood-brain barrier transport
SG11201407343XA (en) Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
SG11201901628XA (en) Methods and compositions for spinal cord cells
SG11201407851RA (en) Synthesis of pyrrolo [2, 3 - b] pyridines
SG11201807881VA (en) Compositions and methods for making antibodies based on use of an expression-enhancing locus
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11201407655TA (en) Therapeutic uses of fibroblast growth factor 21 proteins
SG11201408037SA (en) Humanized anti-trka antibodies with amino acid substitutions